SNYNFPNKHealthcare

Sanofi

-2.7% · 90d

$93.50

+1.06 (+1.15%)

News

(2)

April 2026

Apr 23, 20264 days ago6-K

Sanofi Posts Double-Digit Growth in Sales and Profit for Q1 2026

SNYNFSanofi

# 🔥 The Headline: A Strong Start to 2026 Sanofi kicked off 2026 with a powerful quarter, posting **double-digit growth** in both sales and its key profit metric. This performance signals that the company's strategy—focusing on new specialty drugs and vaccines—is firing on all cylinders. # 💊 What

Read summaryView on SEC EDGAR

March 2026

Mar 31, 20263 weeks ago6-K

Sanofi — 6-K Filing

SNYNFSanofi

# 🧾 What This Document Is This is a **6-K filing** from Sanofi, a French pharmaceutical giant. Think of it as a "news report" the company must submit to the SEC to update investors on major recent events. This specific filing is a bundle of four separate press releases, all announcing important reg

Read summaryView on SEC EDGAR

Key Data

Market Cap$112.01B

Open$93.50

Prev Close$92.44

Day Range$93.50 – $93.50

52W Range$85.74 – $113.69

Volume166

P/E (TTM)20.19

EPS$4.63

Dividend Yield5.34%

Beta0.32

Profit Margin16.72%

Revenue Growth6.90%

Next Earnings2026-04-23

About

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Healthcare · Drug Manufacturers - General

74,846 employees

www.sanofi.com

Top Institutional Holders

As of 2025-12-31 · prior 2025-09-30

Dodge & Cox$2.74B

56,492,599 sh-18.0%

Royal Bank of Canada$130.1M

2,684,198 sh-52.7%

MILLENNIUM MANAGEMENT LLC$10.1M

209,154 sh-90.8%

MORGAN STANLEY$441.1M

9,102,196 sh+20.4%

Capital Research Global Investors$80.0M

1,650,018 sh● NEW

See all holders →